Company
Altimmune, Inc.
Headquarters: Gaithersburg, MD, United States
Employees: 47
CEO: Dr. Vipin K. Garg Ph.D.
Market Cap
$386.1 Million
USD as of July 1, 2025
Altimmune, Inc. Categories
United States Healthcare BiotechnologyUnited States Healthcare United States Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $309.91 B |
| Vertex Pharmaceuticals Incorporated | $117.36 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $59.14 B |
| Marinomed Biotech AG | $58.56 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Novo Nordisk | $309.91 B |
| UnitedHealth Group | $279.90 B |
Detailed Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
Financials
| Last Financial Reports Date | Dec. 31, 2023 |
| Revenue TTM | $426,000 |
| EBITDA | $-83,033,000 |
| Gross Profit TTM | $0 |
| Profit Margin | 0.00% |
| Operating Margin | -57308.11% |
| Quarterly Revenue Growth | -89.78% |
Stocks & Indices
Altimmune, Inc. has the following listings and related stock indices.
Stock: NASDAQ: ALT wb_incandescent
Stock: BMV: ALT1 wb_incandescent
Stock: FSX: 3G0 wb_incandescent